Cytodyn Inc (CYDY)

[Hold10]

2022 lenacapivir mdr-hiv approved: > 87% efficacy
lenacapivir was better than 81%. 87.5% in phase 3.
it is the superior drug for treating mdr-hiv.
and it is approved. leronlimab will almost certainly NEVER gain approval for mdr-hiv.
its not being pursued. never will be. r5 tropic mdr-hiv combo third line therapy consists of less than 5% of all hiv patients.
its not much of a money maker. gilead went after it cuz they dominate hiv and they could afford to punch that out while simultaneously running trials for several other lenacapivir hiv indications that will generate much greater revs.